{
  "id": 6440921,
  "title": "Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances",
  "url": "https://urgent.news/2026/09/09/fate-therapeutics-at-cantor-conference-autoimmune-car-t-push-advances",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-09T16:27:14.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/fate-therapeutics-at-cantor-conference-autoimmune-cart-push-advances-93CH-4894189"
  },
  "original_language": "en",
  "account": "Fate Therapeutics discussed its cell therapy platform and autoimmune CAR-T programs at the 12th Annual Cantor Fitzgerald Global Healthcare Conference. The company highlighted its low-cost master cell bank model and the autoimmune program moving toward a possible registrational path. Fate's master cell bank can produce over 10 million doses, compared to roughly 500 doses from donor T-cell approaches, making cell therapy more uniform, scalable, and affordable. The current 40,000-square-foot manufacturing facility can support 50,000 doses, with the potential to produce more than 50,000 batches. The cost of goods is about $3,000 per dose, significantly lower than other CAR T products. Fate aims to treat nearly 100 patients across oncology and autoimmune disease with no unexpected safety issues, maintaining a favorable safety profile. The lead program, FT819, targets lupus nephritis and is in an open-label, single-arm Phase II study with 53 patients planned and 45 needed for analysis. The primary endpoint is a six-month complete renal response. Early data from FT819 shows a more than 1 gram per gram reduction in UPCR, with 1.8 grams per gram reduction in a bendamustine-enriched group. Another program, FT839, is a dual-targeted CD19 and CD38 CAR T program, with IND clearance and first patient anticipated within months. Fate's approach reduces manufacturing bottlenecks and eliminates variability seen in traditional manufacturing, ensuring consistent safety and efficacy across disease areas.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Relay Therapeutics at Wells Fargo conference: pipeline nears key tests",
        "url": "https://urgent.news/2026/09/08/relay-therapeutics-at-wells-fargo-conference-pipeline-nears-key-tests",
        "published": "2026-09-08T18:19:28.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}